[Immunosuppressive drugs in the treatment of diseases belonging to the psoriasis group].
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001323:Autoantibodies; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D012867:Skin / Q000276:immunology; D013091:Spermatogenesis / Q000187:drug effects
D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D006918:Hydroxyurea; D008727:Methotrexate
Srodki immunosupresyjne w leczeniu chorób kregu łuszczycy